Navigation Links
New England Biolabs and Rubicon Genomics Enter into Distribution Agreement for Single Cell Amplification Products
Date:10/11/2011

IPSWICH, Mass. and ANN ARBOR, Mich., Oct. 11, 2011 /PRNewswire/ -- New England Biolabs, Inc. (NEB) and Rubicon Genomics jointly announce that they have signed a distribution agreement whereby NEB will distribute a product that uses Rubicon's proprietary amplification technology to enable the amplification of DNA from single cells or extremely low amounts of input DNA. The Single Cell Whole Genome Amplification (WGA) Kit is the first product available from NEB targeted at the single cell amplification market, and is expected to find use in numerous research applications, including cancer studies.

(Logo: http://photos.prnewswire.com/prnh/20090921/NE79207LOGO-b)

"New England Biolabs is excited to expand our product portfolio with reagents for single cell amplification, an emerging new area of genomic research," states Dr. Salvatore Russello, Associate Director of Business Development at NEB. "We look forward to facilitating the adoption of this unique technology in basic and applied research worldwide."

"NEB is an outstanding partner and we look forward to working with them to leverage our early successes in the diagnostic market into the research market, an important area of growth for our company," states Jim Koziarz, President and CEO of Rubicon. "This single cell amplification technology has already been widely adopted in the in vitro fertilization (IVF) market, and we are excited at the prospects this product has in research applications."

The Single Cell WGA Kit was released through NEB's global sales and distribution network on October 7th.

About NEB

Established in the mid 1970's, New England Biolabs, Inc. is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, sample preparation for next generation sequencing, cellular analysis, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors. New England Biolabs is a privately held company, headquartered in Ipswich, MA and has extensive worldwide distribution through a network of exclusive distributors, agents and six subsidiaries located in Canada, China, France, Germany, Japan and the UK. For more information about New England Biolabs visit www.neb.com

About Rubicon Genomics

Rubicon, located in Ann Arbor, MI, is a pre-analytical amplification company that has developed and commercialized reagents and kits that increase the analytical and clinical performance of analytical platforms including Q-PCR, microarrays, and Next Generation Sequencing. By producing highly pure DNA of uniform concentration and molecular weight these products increase the sensitivity, specificity, and reproducibility of conventional instrumentation in research and diagnostic applications, including analysis of single cells, formalin-fixed tissue and plasma.  For more information about Rubicon Genomics visit www.rubicongenomics.com.


'/>"/>
SOURCE New England Biolabs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. New England Peptide Names Director of Chemical Development
2. NeoStem Secures $250,000 in an Above Market Financing and Expands Its Relationship With New England Cryogenic Center, Inc.
3. New England Peptide Forms Scientific Advisory Board
4. Gene Therapy Field Advances With Important Clinical Findings Reported in the New England Journal of Medicine
5. New England Journal of Medicine Study Highlights Need for Rapid, PCR-based Group B Streptococcus (GBS) Testing at Time of Admission for Labor and Delivery
6. Data Published in The New England Journal of Medicine Support Use of Raxibacumab (ABthrax(TM)) for the Treatment of Inhalation Anthrax
7. First U.K. Stem Cell Awareness Rally to Take Place in Manchester, England on August 9th, 2009
8. Ontario Institute for Cancer Research Validates NEBNext(TM) DNA Sample Preparation Reagents from New England Biolabs for use in Next Generation Sequencing
9. Wellcome Trust Sanger Institute to use NEBNext(TM) DNA Sample Preparation Reagents from New England Biolabs for Next Generation Sequencing
10. Organogenesis CEO Geoff MacKay and COO / CFO Gary Gillheeney Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Winners in New England
11. New England Biolabs Launches NEBNext(TM) DNA Sample Prep Master Mix Set 3 for Use with SOLiD(TM) 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... , ... Bacterial biofilms, surface adherent communities of bacteria that are encased in ... poisoning and catheter infections to gum disease and the rejection of medical implants. ... per year, there is currently a paucity of means for preventing their formation or ...
(Date:5/22/2017)... ... 22, 2017 , ... Baltimore biotech firm, PathSensors, announced that ... in developing and issuing recommendations to grow Maryland's biohealth industry and position the ... , The recommendations are contained in a report from the ...
(Date:5/19/2017)... New York (PRWEB) , ... May 19, 2017 , ... ... techniques in treating gait disorders, Biodex Medical Systems, Inc. announces the release of their ... music therapy has been joined with a biomedical system to aid in rehabilitating individuals ...
(Date:5/18/2017)... ... May 16, 2017 , ... Clinical Supplies Management (“CSM”), a Great ... company continues to grow. CSM has doubled in size over the past six ... aggressive growth strategy. , Roger Gasper joins CSM as Chief Financial Officer. Roger ...
Breaking Biology Technology:
(Date:4/5/2017)... KEY FINDINGS The global market for stem ... 25.76% during the forecast period of 2017-2025. The rise ... growth of the stem cell market. Download ... The global stem cell market is segmented on the ... cell market of the product is segmented into adult ...
(Date:3/30/2017)... The research team of The Hong Kong ... identification by adopting ground breaking 3D fingerprint minutiae recovery and matching ... and accuracy for use in identification, crime investigation, immigration control, security ... ... A research team led by ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health ... and Management Systems Society (HIMSS) Analytics for achieving ... Adoption Model sm . In addition, CHS previously ... U.S. hospitals using an electronic medical record (EMR). ... its high level of EMR usage in an ...
Breaking Biology News(10 mins):